Imara prices $50M public offering of 8.33M shares at $6.00 each; net proceeds ~$46.8M

Enliven Therapeutics, Inc.

Offering of 8,333,333 shares priced at $6.00/share for gross proceeds of $50M.
Net proceeds expected to be ~$46.8M after underwriting discounts and offering expenses.
Underwriters granted 30-day option to purchase up to 1,249,999 additional shares ($7.5M).
Closing expected July 16, 2021; Morgan Stanley, SVB Leerink, and Cantor are joint book-runners.
Company is a clinical-stage biotech focused on rare hemoglobin disorders; proceeds for general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.